BLOG

pharmas almanac

Fighting Solid Tumors by Targeting Neoantigens in a Personalized Manner

BlueSphere Bio, discusses how the company’s new platform technologies enable the rapid development of effective personalized T cell receptor (TCR) T cell therapies for the treatment of solid tumors with Pharma’s Almanac Editor in Chief David Alvaro, Ph.D.